Anonymize FDA-regulated clinical trial records for electronic submission compliance – CCPA/HIPAA-compliant de-identification per 21 CFR Part 11
Clinical trial records managed under FDA electronic record and signature requirements at 21 CFR Part 11 must be maintained with audit trail integrity. When trial participant records are prepared for publication, sponsor review, or data-sharing submissions, anonym.legal de-identifies participant identifiers while preserving the electronic record structures — audit trails, electronic signatures, and version histories — required by 21 CFR Part 11.
When this applies
Apply this workflow when an FDA-regulated clinical trial's electronic records — eCRFs, informed consent forms, and adverse-event reports — must be shared with a data monitoring committee, sponsor, or submitted to a repository in de-identified form, and 21 CFR Part 11 audit trail integrity must be preserved.
How anonym.legal handles it
- Upload clinical trial electronic records (PDF exports of eCRFs, electronic consent forms, and adverse-event narratives) to anonym.legal.
- The engine identifies participant PHI: name, date of birth, address, SSN, and any other HIPAA Safe Harbor identifiers appearing in trial record headers, consent form fields, and adverse-event narratives.
- All Safe Harbor identifiers are removed; trial-specific non-identifying data — randomization code, treatment arm assignment, dosing records, efficacy endpoint measurements — are preserved.
- Electronic signature metadata (signer role, signature date, signature status) is preserved in de-identified form; the signing individual's name is replaced with a role label.
- Audit trail entries — record creation timestamps, modification history, system access logs — are preserved with user role labels replacing named user identifiers.
- A de-identified record package meeting FDA data submission formatting requirements is produced for sponsor or repository use.
What you provide
- Electronic clinical trial records (PDF eCRF exports, consent forms, adverse-event reports)
- Trial data dictionary identifying PHI-bearing fields
- Informed consent forms (if electronic consent under 21 CFR Part 11 scope)
Limitations & cautions
- 21 CFR Part 11 requires that audit trails documenting record changes be maintained and not altered; the de-identification process generates a new de-identified record set — the original identified trial master file records must be retained separately with intact audit trails.
- FDA may require access to identified trial records during inspections; de-identified copies are not a substitute for the identified trial master file.
- Electronic signature authenticity verification relies on PKI infrastructure linked to the original signer's identity; de-identified records with role labels in place of signer names cannot be used for signature verification under 21 CFR §11.70.
FAQ
Does 21 CFR Part 11 apply to all electronic records in a clinical trial?
21 CFR Part 11 applies to electronic records that are created, modified, maintained, archived, retrieved, or transmitted under FDA requirements. This includes eCRFs, electronic informed consent forms, adverse-event reports submitted electronically, and records related to FDA-regulated drug or device trials. Records maintained for non-FDA purposes are not subject to Part 11.
Can the de-identified trial records be submitted to ClinicalTrials.gov data repositories?
Yes. De-identified participant-level data shared under ClinicalTrials.gov data-sharing plans must be de-identified per HIPAA standards when the trial data also constitutes PHI. This workflow produces data suitable for such submissions when participants are covered by HIPAA.
Are adverse-event narratives processed differently from structured eCRF fields?
Yes. Adverse-event free-text narratives require natural-language entity detection to identify participant names and dates embedded in clinical descriptions. The engine applies NLP-based detection to narrative fields separately from structured field processing, ensuring comprehensive identifier removal.